ReviewClinical and experimental immunology2009
Cytokine and anti-cytokine therapy in asthma: ready for the clinic?
Review in Clinical and experimental immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Interleukin 4 gene polymorphism (-589C/T) and the risk of asthma: a meta-analysis and met-regression based on 55 studies.BMC immunology · 2020Pooled it
- Causality between various cytokines and asthma: a bidirectional two-sample Mendelian randomization analysis.Frontiers in medicine · 2024Article
- Fungal Aeroallergens-The Impact of Climate Change.Journal of fungi (Basel, Switzerland) · 2023Review
- Anti-inflammatory and Antioxidant Effects of Rosuvastatin on Asthmatic, Hyperlipidemic, and Asthmatic-Hyperlipidemic Rat Models.Inflammation · 2021Article
- Review
- Interleukin 9 serum level and single nucleotide polymorphism in patients with asthma.Acta bio-medica : Atenei Parmensis · 2021Article
- Tuo-Min-Ding-Chuan Decoction Alleviate Ovalbumin-Induced Allergic Asthma by Inhibiting Mast Cell Degranulation and Down-Regulating the Differential Expression Proteins.Frontiers in pharmacology · 2021Article
- Effects of catalpol on asthma by airway remodeling via inhibiting TGF-β1 and EGF in ovalbumin-induced asthmatic mice.American journal of translational research · 2020Article
- Intranasal administration ofExperimental and therapeutic medicine · 2019Article
- Inhibitory effects of catalpol coordinated with budesonide and their relationship with cytokines and Interleukin-13 expression.American journal of translational research · 2019Article
- Enhanced effect of catalpol on specific immune therapy in treatment of asthmatic mice.American journal of translational research · 2019Article
- Review
- Biologic agents for severe asthma patients: clinical perspectives and implications.Internal and emergency medicine · 2018Review
- Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease.Therapeutic advances in chronic disease · 2016Review
- Vanin-1 expression and methylation discriminate pediatric asthma corticosteroid treatment response.The Journal of allergy and clinical immunology · 2015Article
- Identify asthma genes across three phases based on protein-protein interaction network.IET systems biology · 2015Article
- Signaling through FcRγ-associated receptors on dendritic cells drives IL-33-dependent TH2-type responses.The Journal of allergy and clinical immunology · 2014Article
- Article
- Severe asthma: an expanding and mounting clinical challenge.The journal of allergy and clinical immunology. In practice · 2013Review
- Antagonism of cytokine-induced eosinophil accumulation in asthma.Frontiers in pharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Asthma is a common disease with an increasing prevalence worldwide. Up to 10% of these patients have asthma that is refractory to current therapy. This group have a disproportionate use of health care resources attributed to asthma, have significant morbidity and mortality and therefore represent an unmet clinical need. Asthma is a complex heterogeneous condition that is characterized by typical symptoms and disordered airway physiology set against a background of airway inflammation and remodelling. The inflammatory process underlying asthma is co-ordinated by a cytokine network. Modulating this network with biological therapy presents a new paradigm for asthma treatment. Clinical trials undertaken to date have underscored the complexity of the inflammatory profile and its relationship to the clinical features of the disease and have raised the importance of safety considerations related to these novel therapies. T helper type 2 cytokine blockade remains the most promising strategy, with anti-interleukin-5 reducing asthma exacerbations. Although anti-cytokine therapy is not yet ready for the clinic, the long-awaited possibility of new treatments for severe asthma is moving ever closer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.